JHS Svendgaard Laboratories growth ratios

Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+10.5%+29.9%−26.4%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+165.2%−327.9%+89.7%
+59.2%−64.2%+56.0%
+90.2%−385.4%+75.8%
+90.7%−355.8%+65.8%
+7.0%+2.1%−16.6%
+1.1%+1.7%−5.8%
+48.7%+42.8%−147.9%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

JHS₹8.19

JHS Svendgaard Laboratories Limited

· FMCG & Retail
₹ CrorePeersBAJAJCONPGHHMcap ₹71.6 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—-26.4+29.9+10.5—
EBITDA Growth—+89.7-327.9+165.2—
EBIT Growth—+56.0-64.2+59.2—
Net Income Growth—+75.8-385.4+90.2—
EPS Growth—+65.8-355.8+90.7—
Total Assets Growth—-16.6+2.1+7.0—
Total Equity Growth—-5.8+1.7+1.1—
Cash from Operations Growth—-147.9+42.8+48.7—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.